{"entity":{"id":"tempus","kind":"company","name":"Tempus AI","aka":[],"tldr":"Genomic testing plus one of the largest multimodal clinical datasets, used for AI models and trial matching; it bought the AI pathology company Paige in August 2025.","summary":"Tempus AI, based in Chicago and listed as TEM, pairs genomic testing with one of the largest multimodal clinical datasets, used to build AI models and match patients to trials. It sells xT, a 648-gene panel with an FDA-approved CDx version, xR for RNA, xF and xM for liquid biopsy and MRD, the TIME trial matching service and algorithms such as Tempus ECG-AF, and it owns Ambry Genetics for germline testing and, since August 2025, the digital pathology company Paige, with Personalis and Deep 6 AI also linked. OnCo links it to comprehensive genomic profiling, AI trial matching, oncology real-world data platforms and multimodal models, and to bottlenecks on AI that is built but not validated, data silos and patient navigation, with ideas on a shared multimodal foundation model attached. Whether its data advantage produces validated clinical tools rather than only revenue is the open question. Tempus xT CDx has its own page.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.tempus.com"},{"label":"Tempus 2025 annual report (SEC)","url":"https://www.sec.gov/Archives/edgar/data/1717115/000119312526145547/d41009dars.pdf"}],"tags":[],"related":[],"cancers":[],"sections":["diagnostics","ai-computation"],"technologies":["cgp","ai-trial-matching"],"targets":[],"drugs":[],"companies":["deep-6-ai","paige"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05736731","nct06051695"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Checked 29 October 2026: Tempus's 2025 annual report states that it completed the acquisition of Paige.AI, Inc. on 22 August 2025 (fair value of consideration 101.5 million US dollars). No later acquisition or change of status was confirmed in this pass; the web search budget ran out before a full sweep of 2026 news."],"hq":"Chicago, IL","country":"US","companyType":"ai-software","website":"https://www.tempus.com","ticker":"TEM","investors":[],"funding":[]},"route":"/companies/tempus/","neighbours":{"section":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/"},{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"ai-trial-matching","kind":"technology","name":"AI trial matching & clinical decision support","route":"/technologies/ai-trial-matching/"},{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"},{"id":"digital-twins-trials","kind":"technology","name":"Digital twins and virtual control arms","route":"/technologies/digital-twins-trials/"},{"id":"oncology-real-world-data","kind":"technology","name":"Oncology EHR and real-world data platforms","route":"/technologies/oncology-real-world-data/"},{"id":"pathology-foundation-model","kind":"technology","name":"Pathology & radiology foundation models","route":"/technologies/pathology-foundation-model/"},{"id":"tempus-multimodal","kind":"technology","name":"Tempus multimodal models","route":"/technologies/tempus-multimodal/"}],"company":[{"id":"deep-6-ai","kind":"company","name":"Deep 6 AI","route":"/companies/deep-6-ai/"},{"id":"paige","kind":"company","name":"Paige AI","route":"/companies/paige/"},{"id":"personalis","kind":"company","name":"Personalis (Tempus)","route":"/companies/personalis/"}],"trial":[{"id":"nct05736731","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression","route":"/trials/nct05736731/"},{"id":"nct06051695","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","route":"/trials/nct06051695/"}],"idea":[{"id":"idea-moon-federated-rwe-network","kind":"idea","name":"A global federated real-world evidence network at regulatory grade","route":"/ideas/idea-moon-federated-rwe-network/"},{"id":"idea-data-precompetitive-cancer-foundation-model","kind":"idea","name":"A pre-competitive consortium to train a shared multimodal cancer foundation model","route":"/ideas/idea-data-precompetitive-cancer-foundation-model/"},{"id":"idea-tr2-tmb-calibration-standard","kind":"idea","name":"A single calibrated tumour mutational burden across all sequencing panels","route":"/ideas/idea-tr2-tmb-calibration-standard/"},{"id":"idea-tr2-rwe-combination-emulation","kind":"idea","name":"Emulate combination trials from real-world data to triage which ones to run","route":"/ideas/idea-tr2-rwe-combination-emulation/"},{"id":"idea-data-structured-genomic-reports","kind":"idea","name":"Every tumour genomic report machine-readable and deposited nationally","route":"/ideas/idea-data-structured-genomic-reports/"},{"id":"idea-tr1-ngs-report-live-trial-match","kind":"idea","name":"Every tumour sequencing report lists open, nearby, matched trials pulled live","route":"/ideas/idea-tr1-ngs-report-live-trial-match/"},{"id":"idea-bio1-truncal-branch-labelling","kind":"idea","name":"Label every targetable mutation as truncal or branch on the report","route":"/ideas/idea-bio1-truncal-branch-labelling/"},{"id":"idea-multimodal-foundation-model","kind":"idea","name":"Patient-level multimodal foundation models for treatment selection","route":"/ideas/idea-multimodal-foundation-model/"},{"id":"idea-tr1-ehr-point-of-care-trial-alert","kind":"idea","name":"Trial matching inside the electronic record at the moment a treatment is chosen","route":"/ideas/idea-tr1-ehr-point-of-care-trial-alert/"},{"id":"idea-data-rwpfs-validation-programme","kind":"idea","name":"Validate real-world progression against central imaging review","route":"/ideas/idea-data-rwpfs-validation-programme/"},{"id":"idea-tr2-antagonism-surveillance","kind":"idea","name":"Watch routine care for drug combinations that quietly make cancer treatment worse","route":"/ideas/idea-tr2-antagonism-surveillance/"}],"bottleneck":[{"id":"b-ai-validation","kind":"bottleneck","name":"AI that is built but not validated or deployed","route":"/bottlenecks/b-ai-validation/"},{"id":"b-data-silos","kind":"bottleneck","name":"Data silos","route":"/bottlenecks/b-data-silos/"},{"id":"b-care-fragmentation","kind":"bottleneck","name":"Fragmented care and guideline gaps","route":"/bottlenecks/b-care-fragmentation/"},{"id":"b-immunotherapy-response","kind":"bottleneck","name":"No one can predict who responds to immunotherapy","route":"/bottlenecks/b-immunotherapy-response/"},{"id":"b-patient-voice","kind":"bottleneck","name":"Patients lack understanding, navigation and agency","route":"/bottlenecks/b-patient-voice/"},{"id":"b-trial-enrolment","kind":"bottleneck","name":"Trials enrol too few, too slowly","route":"/bottlenecks/b-trial-enrolment/"},{"id":"b-real-world-evidence","kind":"bottleneck","name":"Weak real-world evidence and registries","route":"/bottlenecks/b-real-world-evidence/"}],"drug":[{"id":"tempus-xt-cdx","kind":"drug","name":"Tempus xT CDx","route":"/drugs/tempus-xt-cdx/"}],"roadmap":[{"id":"ai-oncology-roadmap","kind":"roadmap","name":"AI in oncology roadmap: pattern readers → foundation models → agents in the workflow","route":"/roadmaps/ai-oncology-roadmap/"},{"id":"trial-modernisation-roadmap","kind":"roadmap","name":"Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on","route":"/roadmaps/trial-modernisation-roadmap/"}]}}